Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2022
      • World Mitochondrial Disease Week 2021
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Press releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
22 November, 2016
Regulatory

NeuroVive Pharmaceutical AB Interim Report January – September 2016

New business model generates opportunities
Continue reading
8 November, 2016
Regulatory

NeuroVive’s recruitment of Michele Tavecchio strengthens its research organization

Lund, Sweden, November 8, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the company has recruited Michele Tavecchio ...
Continue reading
1 November, 2016
Regulatory

NeuroVive reports positive pre-clinical results in NASH

Lund, Sweden, November 1, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive pre-clinical results with one of its cy ...
Continue reading
26 October, 2016
Regulatory

NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee

Lund, Sweden, October 26, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the Annual General Meeting of NeuroVive Pha ...
Continue reading
25 October, 2016
Regulatory

NeuroVive completes closure of Lyon subsidiary

Lund, Sweden, October 25, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has completed the closure of its dormant ...
Continue reading
21 October, 2016
Regulatory

NeuroVive and Arbutus sign termination agreement

Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the license agreement with Arbutus Biopharm ...
Continue reading
13 October, 2016
Regulatory

NeuroVive discontinues development of CicloMulsion for acute kidney injury

Lund, Sweden, October 13, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced results from the exploratory clinical phase II s ...
Continue reading
7 September, 2016
Regulatory

NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Lund, Sweden, September 7, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the company is scheduled to present at the ...
Continue reading
30 August, 2016
Regulatory

NeuroVive announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in October 2016

Lund, Sweden, August 30, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the clinical study CiPRICS will be presented ...
Continue reading
24 August, 2016
Regulatory

NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company

Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its Chief Operating Officer, Jan Nilsson lea ...
Continue reading
18 August, 2016
Regulatory

NeuroVive Pharmaceutical – Interim report January-June 2016

Business operations
Continue reading
15 August, 2016
Regulatory

NeuroVive completes 10 percent acquisition of Isomerase Therapeutics

Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the second step in the previously announced ...
Continue reading

Posts navigation

Older posts

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all